ISRCTN55371988已完成未知
Study of immunogenicity and effectiveness of BNT162b2 in healthcare workers and oncological/immunocompromised patients at Istituti Fisioterapici Ospitalieri.
Istituti Fisioterapici Ospitalieri0 个研究点目标入组 2,000 人开始时间: 2021年2月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 2,000
研究概览
简要总结
2021 Other publications in https://doi.org/10.3390/vaccines9070685 Correlation with age, gender and BMI (added 05/08/2021) 2021 Other publications in https://doi.org/10.1016/j.eclinm.2021.100928 Effect of age, gender and BMI on vaccine response (added 05/08/2021) 2021 Results article in https://doi.org/10.3390/vaccines9101125 (added 06/03/2024)
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Provided written informed consent
- •2. Oncological/immunocompromised patient at the Istituti Fisioterapici Ospitalieri (IFO) or health worker employed at the Istituti Fisioterapici Ospitalieri
- •3. Vaccinated at the Istituti Fisioterapici Ospitalieri
排除标准
- •1. Evidence of current or previous SARS-CoV-2 infection by either anamnesis, serological or microbiological test through nasopharyngeal swab before enrolment
研究者
相似试验
已完成
不适用
Covid-19 Vaccine Response in Elderly SubjectsCovid19 VaccineNCT04760704University Hospital, Lille264
已完成
不适用
Immunogenicity and safety of BNT162b2 mRNA vaccine in outpatients on dialysis: Double center prospective observational study in Japadialysis patientsJPRN-UMIN000044500Shonan Fujisiawa Tokushukai Hospital150
已完成
1 期
Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male SubjectsHealthyNCT04621318Samsung Bioepis Co., Ltd.168
Unknown
不适用
Humoral and Cellular Responses to Vaccination Against Coronavirus Disease 2019 (COVID-19) in the Very Elderly Living in Geriatric InstitutionsElderly People Institutionalized in Long-term Care ServicesNCT04961502Gérond'if80
已完成
2 期
Safety and Immunogenicity of SARS CoV-2 mRNA vaccine platform in healthy Thai adolescent (COVID-19)Prevention of COVID-19 with SARS CoV-2 mRNA vaccine platform, comparing standard dose and low dose, in healthy Thai adolescentSARS-CoV-2, mRNA vaccine, COVID-19 vaccine, Adolescent, Immunogenicity, ReactogenicityTCTR20210917004ational Vaccine Institute120